Quarterly ResultAug 13, 2026, 04:09 PM
Vivani Medical Q2 Net Loss $(6.37)M; Raises Going Concern Doubt
AI Summary
Vivani Medical, a clinical-stage biopharmaceutical company, reported a net loss of $(6.37) million for the second quarter of 2026, an improvement from $(7.14) million in the prior year. The company's management has raised substantial doubt about its ability to continue as a going concern, as existing cash is projected to fund operations only through the second quarter of 2027. To address liquidity, its subsidiary Cortigent entered a merger agreement with ClearOne, Inc., which aims to raise $10 million to $15 million concurrently with the merger's closing.
Key Highlights
- Net loss for Q2 2026 was $(6.37) million, an improvement from $(7.14) million in Q2 2025.
- Net loss per common share for Q2 2026 was $(0.07), compared to $(0.12) in Q2 2025.
- Vivani Medical expects existing cash to fund operations only through Q2 2027.
- Management raises substantial doubt about the company's ability to continue as a going concern.
- Subsidiary Cortigent entered a merger agreement with ClearOne, Inc. on July 1, 2026.
- ClearOne is pursuing $10M-$15M financing concurrent with the Cortigent merger closing.
- Cash and cash equivalents increased to $19.89 million as of June 30, 2026, from $16.23 million.
Price Impact
More from VANI